Dual Target Molecular Imaging in precision management of breast cancer: The time has come
Main Article Content
Abstract
No abstract as it is an editorial commentary
Article Details
How to Cite
CHOUDHURY, Partha; GUPTA, Manoj.
Dual Target Molecular Imaging in precision management of breast cancer: The time has come.
Medical Research Archives, [S.l.], v. 5, n. Issue 9, sep. 2017.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/1489>. Date accessed: 13 nov. 2024.
Keywords
Breast Cancer, Estrogen Receptor, FES imaging
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
References:
1. Fisher B,Costantino J, Redmond C, Poisson R, Bowman D et al. A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N. Engl J Med 1989;320 : 479-84
2. Ellis Mathew J, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janike F. Letrozole is more effective neoadjuvant endocrine therapy than Tamoxifen for ErbB-1 and/or ErbB2-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 Sept 2001; (18) 3808-16.
3. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al. Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor positive breast cancer. J. Clin Oncol; 24 Aug 2006 (23) : 3726-34
4. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor –positive breast cancer. Nature Genetics 2008; 40 : 703-06.
5. Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC et al. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple negative breast cancer. Eur J Nucl Med Mol Imaging. 2016; 43(11) : 1937-44
6. Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS et al. Comparison of FDG PET/CT and contrast enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging 2017; 44(9) : 1428-37
7. Rosen EL, Eubank WB, Mankoff DA. 18F‑FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27 Suppl 1:S215‑29.
8. Groheux D, Espié M, Giacchetti S, Hindié E. Performance of 18F‑FDG PET/CT in the clinical management of breast cancer. Radiology 2013;266:388‑405.
9. Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G. Clinical utility of F‑18 18F‑FDG PET/CT in recurrent breast carcinoma. Nucl Med Commun 2012;33:591‑6.
10. Eubank WB. Diagnosis of recurrent and metastatic disease using f‑18 fluorodeoxyglucose‑positron emission tomography in breast cancer. Radiol Clin North Am 2007;45:659‑67.
11. Isasi CR, Moadel RM, Blaufox MD. A meta‑analysis of 18F‑FDG‑PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105‑12.
12. Dehdasti F, Mortimer JE, Siegel BA, Griffeth et al. Positron tomographic assessment of estrogen receptors in breast cancer : comparison with 18F-FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-74
13. Mintun MA, Welch MJ, Siegel BA, Mathias CJ et al. Breast Cancer : PET imaging of estrogen receptors. Radiology 1988;169 : 45-8
14. Mc Guire AH, Dehdasti F, Seigel BA, Lyss AP et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32: 1526-31
15. Peterson LM, Mankoff DA, Lawton T, Yagle K et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008; 49 : 367-74
16. Mortimer JE, Dehdasti F, Siegel BA, Katzenellenbogen JA et al. Positron emission tomography with 2-[18F] Fluoro-2-deoxy-D-glucose and 16 alpha-[18F] fluoro-17 beta estradiol in breast cancer : Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996; 2 : 933-9
17. Chae SY, Kim SB, Ahn SH, et al. A randomized feasibility study of 18F- fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer. J Nucl Med. 2017;58: 563-68
18. Yang Z, Sun Y, Xue J et al. Can positron emission tomography/computed tomography with dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer? A pilot study. PLoS One 2013; 8 :e78192
19. Gupta M, Datta A, Choudhury PS, et al. Can 18F-Fluoroestradiol Positron Emission Tomography Become a New Imaging Standard in the Estrogen Receptor‑positive Breast Cancer Patient: A Prospective Comparative Study with 18F‑Fluorodeoxyglucose Positron Emission Tomography? World J Nucl Med 2017;16:133-9.
20. Choudhury PS. Developing a personalized treatment model based on molecular biomarkers and imaging in breast cancer: Has the time come? Indian J Nucl Med 2016;31:165.
1. Fisher B,Costantino J, Redmond C, Poisson R, Bowman D et al. A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N. Engl J Med 1989;320 : 479-84
2. Ellis Mathew J, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janike F. Letrozole is more effective neoadjuvant endocrine therapy than Tamoxifen for ErbB-1 and/or ErbB2-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 Sept 2001; (18) 3808-16.
3. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al. Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor positive breast cancer. J. Clin Oncol; 24 Aug 2006 (23) : 3726-34
4. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor –positive breast cancer. Nature Genetics 2008; 40 : 703-06.
5. Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC et al. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple negative breast cancer. Eur J Nucl Med Mol Imaging. 2016; 43(11) : 1937-44
6. Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS et al. Comparison of FDG PET/CT and contrast enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging 2017; 44(9) : 1428-37
7. Rosen EL, Eubank WB, Mankoff DA. 18F‑FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27 Suppl 1:S215‑29.
8. Groheux D, Espié M, Giacchetti S, Hindié E. Performance of 18F‑FDG PET/CT in the clinical management of breast cancer. Radiology 2013;266:388‑405.
9. Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G. Clinical utility of F‑18 18F‑FDG PET/CT in recurrent breast carcinoma. Nucl Med Commun 2012;33:591‑6.
10. Eubank WB. Diagnosis of recurrent and metastatic disease using f‑18 fluorodeoxyglucose‑positron emission tomography in breast cancer. Radiol Clin North Am 2007;45:659‑67.
11. Isasi CR, Moadel RM, Blaufox MD. A meta‑analysis of 18F‑FDG‑PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105‑12.
12. Dehdasti F, Mortimer JE, Siegel BA, Griffeth et al. Positron tomographic assessment of estrogen receptors in breast cancer : comparison with 18F-FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-74
13. Mintun MA, Welch MJ, Siegel BA, Mathias CJ et al. Breast Cancer : PET imaging of estrogen receptors. Radiology 1988;169 : 45-8
14. Mc Guire AH, Dehdasti F, Seigel BA, Lyss AP et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32: 1526-31
15. Peterson LM, Mankoff DA, Lawton T, Yagle K et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008; 49 : 367-74
16. Mortimer JE, Dehdasti F, Siegel BA, Katzenellenbogen JA et al. Positron emission tomography with 2-[18F] Fluoro-2-deoxy-D-glucose and 16 alpha-[18F] fluoro-17 beta estradiol in breast cancer : Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996; 2 : 933-9
17. Chae SY, Kim SB, Ahn SH, et al. A randomized feasibility study of 18F- fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer. J Nucl Med. 2017;58: 563-68
18. Yang Z, Sun Y, Xue J et al. Can positron emission tomography/computed tomography with dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer? A pilot study. PLoS One 2013; 8 :e78192
19. Gupta M, Datta A, Choudhury PS, et al. Can 18F-Fluoroestradiol Positron Emission Tomography Become a New Imaging Standard in the Estrogen Receptor‑positive Breast Cancer Patient: A Prospective Comparative Study with 18F‑Fluorodeoxyglucose Positron Emission Tomography? World J Nucl Med 2017;16:133-9.
20. Choudhury PS. Developing a personalized treatment model based on molecular biomarkers and imaging in breast cancer: Has the time come? Indian J Nucl Med 2016;31:165.